Exosome Manufacturing

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the current status of exosome development and manufacturing services market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to exosomes, types of extracellular vesicles and composition of exosomes. Further, the chapter presents details on the various therapeutic applications of exosomes, advantages and challenges associated with the development and manufacturing of exosomes along with the future perspectives. In addition, the chapter provides information on the isolation, characterization, manufacturing and outsourcing of exosome related services.

Chapter 4 includes information on more than 45 exosome service providers that are currently offering services related to exosomes, and a detailed analysis based on several parameters, such as types of service(s) offered, method of isolation, method of purification, method of characterization, method of exosome manufacturing, scale of operation and scalability. In addition, it provides details on the companies along with information on their year of establishment, company size and location of headquarters.

Chapter 5 provides a competitiveness analysis of exosomes service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development, scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).

Chapter 6 includes detailed profiles of prominent players offering exosome related services. Each profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.

Chapter 7 features an insightful analysis of the partnerships that have been established in this domain, during the period between 2016 and 2021 (till November)., covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements. 

Chapter 8 features a detailed review of peer-reviewed, scientific articles related to research on exosomes, on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).

Chapter 9 features an analysis of the global events attended by the service providers, based on several parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.

Chapter 10 presents an overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.

Chapter 11 provides an insightful analysis of the patents filed / granted for exosomes during the period between 2016 and 2021 (till November) taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus area, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.

Chapter 12 provides information on completed and ongoing clinical studies of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials), emerging focus areas and  location of the trials (on basis of number of registered trials and enrolled patient population).

Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the exosome development and manufacturing services market, till the year 2035. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 14 summarizes the entire report, highlighting various facts related to contemporary market trend and the likely evolution of the exosome development and manufacturing services market. 

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented detailed transcripts of interviews held with (in alphabetical order) Jonathan Carson (Strategic Marketing Manager, RoosterBio), Navdeep Singh (Product Manager and Technical Lead, Clara Biotech) and Nicolas Rousseau (Chief Compliance Officer and Co-founder, EVerZom).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Extracellular Vesicles
3.2.1. Apoptotic bodies: An Overview
3.2.2. Micro vesicles: An Overview
3.2.3. Exosomes: An Overview
3.3. Composition of Exosomes
3.4. Exosome Biogenesis
3.5 Exosome Development: An Overview
3.5.1. Methods for Isolation of Exosomes
3.5.2. Methods for Purification of Exosomes
3.5.3. Methods for Characterization of Exosomes
3.6. Manufacturing of Exosomes
3.7. Outsourcing of Exosomes related Services
3.8. Therapeutic Applications of Exosomes
3.8.1. Modification of Immune System
3.8.2. Exosomes as Targeted Drug Delivery Vehicles
3.8.3. Engineered Exosomes
3.9. Challenges Associated with the Development and Manufacturing of Exosomes
3.9.1. Lack of Standardized Isolation and Purification Methods
3.9.2. Limited Drug Loading Ability
3.9.3. Inadequate Clinical Grade Production
3.10. Future Perspectives

4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Exosome Service Providers: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Headquarters and Company Size
4.3. Analysis by Type of Service(s) Offered
4.3.1. Analysis by Method of Isolation
4.3.2. Analysis by Method of Purification
4.3.3. Analysis by Method of Characterization
4.3.4. Analysis by Method of Exosome Manufacturing
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Scalability

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Scope and Methodology
5.4. Company Competitiveness Analysis: Exosome Service Providers in North America
5.5. Company Competitiveness Analysis: Exosome Service Providers in Europe
5.6. Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Creative Bioarray
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2 Creative Biolabs
6.2.2.1 Company Overview
6.2.2.2 Service Portfolio
6.2.2.3 Recent Developments and Future Outlook

6.2.3. Creative Biostructure
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook

6.3. Key Players based in Europe
6.3.1. Amsbio
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Cambridge Bioscience
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook

6.3.3. Lonza
6.3.3.1 Company Overview
6.3.3.2. Financial Information
6.3.3.3. Service Portfolio
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook

6.3.4. Qiagen
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook

6.4. Key Players based in Asia-Pacific
6.4.1. Exopharm
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Service Portfolio
6.4.1.4. Recent Developments and Future Outlook

6.4.2. Sumika Chemical Analysis Service
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Exosome Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Type of Service Offered
7.3.6. Word Cloud Analysis: Emerging Focus Areas
7.3.7. Analysis by Target Disease Indication
7.3.8. Analysis by Therapeutic Area
7.3.9. Analysis by Type of Technology
7.3.10. Most Active Players: Analysis by Number of Partnerships
7.3.11. Analysis by Type of Service Offered and Type of Partnership
7.3.12. Analysis by Target Disease Indication and Type of Partnership
7.3.13. Regional Analysis
7.3.14. Intercontinental and Intracontinental Agreements

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Service Offered
8.2.3. Word Cloud Analysis: Emerging Focus Areas
8.2.4. Popular Journals: Analysis by Number of Publications
8.2.5. Popular Journals: Analysis by Journal Impact Factor

9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Location of Event
9.3.5. Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
9.3.6. Most Active Organizers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Most Active Speakers: Analysis by Number of Events
9.3.12. Geographical Mapping of Upcoming Events

10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
10.1. Chapter Overview
10.2. Exosome Technologies: An Overview
10.3. List of Exosome Technology Providers
10.3.1. Exosome Technology Providers: Analysis by Year of Establishment
10.3.2. Exosome Technology Providers: Analysis by Company Size
10.3.3. Exosome Technology Providers: Analysis by Location of Headquarters
10.4 Exosome Technologies: Information of Technology Related Services and Therapeutic Applications
10.4.1 Summary

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Exosomes Technologies: Patent Analysis
11.3.1. Analysis by Type of Patent
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Application Year
11.3.4. Analysis by Geographical Location
11.3.5. Analysis by CPC Symbols
11.3.6. Word Cloud Analysis: Emerging Focus Areas
11.3.7. Analysis Type of Organization
11.3.8. Leading Industry Players: Analysis by Number of Patents
11.3.9. Leading Non-Industry Players: Analysis by Number of Patents
11.3.10. Leading Patent Assignees: Analysis by Number of Patents
11.4. Exosome Technologies: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics (CPC Symbols)
11.5 Analysis of Patents by Age
11.6. Patent Valuation Analysis
11.7. Leading Patents by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Trial Status
12.4. Analysis by Trial Registration Year
12.5. Analysis by Trial Registration Year and Enrolled Patient Population
12.6. Analysis by Trial Recruitment Status
12.7. Analysis by Trial Phase and Number of Patients Enrolled
12.8. Analysis by Study Design
12.9. Analysis by Type of Sponsor / Collaborator
12.10. Leading Players: Analysis by Number of Registered Trials
12.11. Word Cloud Analysis: Emerging Focus Areas
12.12. Geographical Analysis by Number of Registered Trails
12.13. Geographical Analysis by Enrolled Patient Population

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Exosome Development and Manufacturing Services: Technology Licensing Model
13.4. Global Exosome Development and Manufacturing Services Market, 2022-2035
13.4.1. Global Exosome Development and Manufacturing Services Market: Distribution by Stage of Application, 2022 and 2035
13.4.1.1. Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
13.4.1.2. Global Exosome Development and Manufacturing Services Market for Clinical Stage
13.4.3. Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
13.4.3.1. Exosome Development and Manufacturing Services Market in North America, 2022-2035
13.4.3.2. Exosome Development and Manufacturing Services Market in Europe, 2022-2035
13.4.3.3. Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
13.4.3.4. Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. EVerZom
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nicolas Rousseau, Chief Compliance Officer and Cofounder
15.3. Clara Biotech
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Navdeep Singh, Product Manager and Technical Lead
15.4. RoosterBio
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jonathan Carson, Strategic Marketing Manager

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Overall Market Landscape of Exosome Development and Manufacturing Services
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Global Events
Figure 2.6 Executive Summary: Overall Market Landscape of Exosomes Technologies
Figure 2.7 Executive Summary: Patent Analysis
Figure 2.8 Executive Summary: Clinical Trial Analysis
Figure 3.1 Exosome Biogenesis
Figure 3.2 Methods for Isolation of Exosomes
Figure 3.3 Methods for Purification of Exosomes
Figure 3.4 Methods for Characterization of Exosomes
Figure 4.1 Exosome Service Providers: Distribution by Year of Establishment
Figure 4.2 Exosome Service Providers: Distribution by Company Size
Figure 4.3 Exosome Service Providers: Distribution by Location of Headquarters
Figure 4.4 Exosome Service Providers: Distribution by Location of Headquarters and Company Size
Figure 4.5 Exosome Service Providers: Distribution by Type of Service(s) Offered
Figure 4.6 Exosome Service Providers: Distribution by Method(s) of Isolation
Figure 4.7 Exosome Service Providers: Distribution by Method(s) of Purification
Figure 4.8 Exosome Service Providers: Distribution by Method(s) of Characterization
Figure 4.9 Exosome Service Providers: Distribution by Method(s) of Exosome Manufacturing
Figure 4.10 Exosome Service Providers: Distribution by Scale of Operation
Figure 4.11 Exosome Service Providers: Distribution by Scalability
Figure 5.1 Company Competitiveness Analysis: Exosome Service Providers in North America
Figure 5.2 Company Competitiveness Analysis: Exosome Service Providers in Europe
Figure 5.3 Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World
Figure 6.1 Lonza: Annual Revenues, 2016-Q2 2021 (CHF Billion)
Figure 6.2 Qiagen: Annual Revenues, 2016-Q3 2021 (CHF Billion)
Figure 6.3 Exopharm: Annual Revenues, 2018- Q2 2021 (CHF Million)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021 (till November)
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2016-2021 (till November)
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Service Offered
Figure 7.6 Word Cloud Analysis: Emerging Focus Areas
Figure 7.7 Partnerships and Collaborations: Distribution by Disease Indication
Figure 7.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.9 Partnerships and Collaborations: Distribution by Type of Technology
Figure 7.10 Most Active Players: Distribution by Number of Partnerships
Figure 7.11 Partnerships and Collaborations: Distribution by Type of Service Offered and Type of Partnership
Figure 7.12 Partnerships and Collaborations: Distribution by Disease Indication and Type of Partnership
Figure 7.13 Partnerships and Collaborations: Regional Distribution
Figure 7.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till November)
Figure 8.2 Publication Analysis: Distribution by Type of Service Offered
Figure 8.3 Publication Analysis: Word Cloud of Study Titles
Figure 8.4 Popular Journals: Distribution by Number of Publications
Figure 8.5 Popular Journals: Distribution by Journal Impact Factor
Figure 9.1 Global Events: Cumulative Half Yearly Trend, H1 2017-H2 2021
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Location of Event
Figure 9.5 Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Industry Participants: Distribution by Number of Events
Figure 9.8 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.9 Global Events: Distribution by Designation of Participant
Figure 9.10 Global Events: Distribution by Affiliated Department of Participant
Figure 9.11 Most Active Speakers: Distribution by Number of Events
Figure 9.12 Global Events: Geographical Mapping of Upcoming Events
Figure 10.1 Exosome Technology Providers: Distribution by Year of Establishment
Figure 10.2 Exosome Technology Providers: Distribution by Company Size
Figure 10.3 Exosome Technology Providers: Distribution by Location of Headquarters
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021 (till November)
Figure 11.3 Patent Analysis: Cumulative Distribution by Application Year, Pre-2016-2021 (till November)
Figure 11.4 Patent Analysis: Distribution by Geographical Location
Figure 11.5 Patent Analysis: Distribution by CPC Symbols
Figure 11.6 Word Cloud: Emerging Focus Areas
Figure 11.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Patent Analysis: Leading Individual Assignees
Figure 11.11 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 11.12 Patent Analysis: Distribution of Patents by Age (2001-2020)
Figure 11.13 Exosome Technologies: Patent Valuation Analysis
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2021
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2016-2021
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 12.6 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Figure 12.7 Clinical Trial Analysis: Distribution by Study Design
Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Leading Players: Distribution by Number of Registered Trials
Figure 12.10 Word Cloud: Emerging Focus Areas
Figure 12.11 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 12.12 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Exosomes Technologies: Information on Licensing Deals
Figure 13.3 Global Exosome Development and Manufacturing Services Market, 2022-2035
Figure 13.3 Global Exosome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Figure 13.4 Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
Figure 13.5 Global Exosome Development and Manufacturing Services Market for Clinical Stage
Figure 13.6 Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
Figure 13.7 Exosome Development and Manufacturing Services Market in North America, 2022-2035
Figure 13.8 Exosome Development and Manufacturing Services Market in Europe, 2022-2035
Figure 13.9 Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
Figure 13.10 Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035
Figure 14.1 Concluding Remarks: Market Landscape of Exosome Development and Manufacturing Services
Figure 14.2 Concluding Remarks: Company Competitiveness Analysis
Figure 14.3 Concluding Remarks: Partnership and Collaborations
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Global Event Analysis
Figure 14.6 Concluding Remarks: Market Landscape of Exosome Technology Providers
Figure 14.7 Concluding Remarks: Patent Analysis
Figure 14.8 Concluding Remarks: Clinical Trial Analysis
Figure 14.9 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Protein Family of Exosomes
Table 4.1 Exosome Service Providers: List of Industry Players
Table 4.2 Exosome Service Providers: Information on Type of Service(s) Offered
Table 4.3 Exosome Service Providers: Information on Method(s) of Isolation
Table 4.4 Exosome Service Providers: Information on Method(s) of Purification
Table 4.5 Exosome Service Providers: Information on Method(s) of Characterization
Table 4.6 Exosome Service Providers: Information on Method(s) of Exosome Manufacturing
Table 4.7 Exosome Service Providers: Information on Scale of Operation
Table 4.8 Exosome Service Providers: Information on Scalability
Table 6.1 Exosome Service Providers: List of Companies Profiled
Table 6.2 Creative Bioarray: Company Snapshot
Table 6.3 Creative Bioarray: Recent Developments and Future Outlook
Table 6.4 Creative Biolabs: Company Snapshot
Table 6.5 Creative Biolabs: Recent Developments and Future Outlook
Table 6.6 Creative Biostructure: Company Snapshot
Table 6.7 Creative Biostructure: Recent Developments and Future Outlook
Table 6.8 Amsbio: Company Snapshot
Table 6.9 Amsbio: Recent Developments and Future Outlook
Table 6.10 Cambridge Biosciences: Company Snapshot
Table 6.11 Cambridge Biosciences: Recent Developments and Future Outlook
Table 6.12 Lonza: Company Snapshot
Table 6.13 Lonza: Information on Manufacturing Facilities
Table 6.14 Lonza: Recent Developments and Future Outlook
Table 6.15 Qiagen: Company Snapshot
Table 6.16 Qiagen: Recent Developments and Future Outlook
Table 6.17 Exopharm: Company Snapshot
Table 6.18 Exopharm: Recent Developments and Future Outlook
Table 6.19 Sumika Chemical Analysis Service: Company Snapshot
Table 7.1 Exosome Service Providers: List of Partnerships and Collaborations, 2016-2021 (till November)
Table 9.1 List of Global Events related to Exosomes
Table 10.1 Exosome Technology Providers: Information on Technology Platforms
Table 10.2 Technology Providers: Information on Technology Related Services and Therapeutic Applications
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: List of Top CPC Symbols
Table 11.3 Patent Analysis: Most Popular CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 15.1 Rooster Bio: Key Highlights
Table 16.1 Exosome Service Providers: Distribution by Year of Establishment
Table 16.2 Exosome Service Providers: Distribution by Company Size
Table 16.3 Exosome Service Providers: Distribution by Location of Headquarters
Table 16.4 Exosome Service Providers: Distribution by Location of Headquarters and Company Size
Table 16.5 Exosome Service Providers: Distribution by Type of Services Offered
Table 16.6 Exosome Service Providers: Distribution by Method(s) of Isolation
Table 16.7 Exosome Service Providers: Distribution by Method(s) of Purification
Table 16.8 Exosome Service Providers: Distribution by Method(s) of Characterization
Table 16.9 Exosome Service Providers: Distribution by Method(s) of Exosome Manufacturing
Table 16.10 Exosome Service Providers: Distribution by Scale of Operation
Table 16.11 Exosome Service Providers: Distribution by Scalability
Table 16.12 Lonza: Annual Revenues, 2016-H1 2021 (CHF Billion)
Table 16.13 Qiagen: Annual Revenues, 2016-9M 2021 (CHF Billion)
Table 16.14 Exopharm: Annual Revenues, 2018- 2021 (CHF Million)
Table 16.15 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021 (till November)
Table 16.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.17 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2016-2021 (till November)
Table 16.18 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.19 Partnerships and Collaborations: Distribution by Type of Service
Table 16.20 Partnerships and Collaborations: Distribution by Type of Disease Indication(s)
Table 16.21 Partnerships and Collaborations: Distribution by Type of Therapeutic Area
Table 16.22 Partnerships and Collaborations: Distribution by Type of Technology
Table 16.23 Most Active Players: Distribution by Number of Partnerships
Table 16.24 Partnerships and Collaborations: Distribution by Type of Service and Type of Partnership
Table 16.25 Partnerships and Collaborations: Distribution by Disease Indication and Type of Partnership
Table 16.26 Partnerships and Collaborations: Regional Distribution
Table 16.27 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.28 Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till November)
Table 16.29 Publication Analysis: Distribution by Type of Service Offered
Table 16.30 Popular Journals: Distribution by Number of Publications
Table 16.31 Popular Journals: Distribution by Journal Impact Factor
Table 16.32 Global Events: Cumulative Half Yearly Trend, H1 2017-H2 2021
Table 16.33 Global Events: Distribution by Event Platform
Table 16.34 Global Events: Distribution by Type of Event
Table 16.35 Global Events: Distribution by Location of Event
Table 16.36 Global Events: Distribution by Event Organizers
Table 16.37 Most Active Industry Participants: Distribution by Number of Events
Table 16.38 Most Active Non-Industry Participants: Distribution by Number of Events
Table 16.39 Global Events: Distribution by Designation of Participant
Table 16.40 Global Events: Distribution by Affiliated Department of Participant
Table 16.41 Most Active Speakers: Distribution by Number of Events
Table 16.42 Technology Providers: Distribution of Developers by Year of Establishment
Table 16.43 Technology Providers: Distribution of Developers by Company Size
Table 16.44 Technology Providers: Distribution of Developers by Region
Table 16.45 Patent Analysis: Distribution by Type of Patent
Table 16.46 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021 (till November)
Table 16.47 Patent Analysis: Cumulative Distribution by Application Year, Pre-2016-2021
Table 16.48 Patent Analysis: Distribution by Geographical Location
Table 16.49 Patent Analysis: Distribution by CPC Symbols
Table 16.50 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 16.51 Leading Industry Players: Distribution by Number of Patents
Table 16.52 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.53 Patent Analysis: Leading Individual Assignees
Table 16.54 Patent Analysis: Distribution of Patents by Age (2001-2020)
Table 16.55 Exosome Technologies: Patent Valuation Analysis
Table 16.56 Clinical Trial Analysis: Distribution by Trial Status
Table 16.57 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2021
Table 16.58 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2016-2021
Table 16.59 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 16.60 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 16.61 Clinical Trial Analysis: Distribution by Study Design
Table 16.62 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.63 Most Active Players: Distribution by Number of Registered Trials
Table 16.64 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 16.65 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 16.66 Licensing Agreements: Distribution of Financial Components
Table 16.67 Exosomes Technologies: Information on Licensing Deals
Table 16.68 Global Exosome Development and Manufacturing Services Market, 2022-2035
Table 16.69 Global Exosome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Table 16.70 Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
Table 16.71 Global Exosome Development and Manufacturing Services Market for Clinical Stage
Table 16.72 Global Exosome Development and Manufacturing Services Market: Distribution by Region, Conservative, Base and Optimistic Scenarios, 2022 and 2035
Table 16.73 Exosome Development and Manufacturing Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.74 Exosome Development and Manufacturing Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.75 Exosome Development and Manufacturing Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.76 Exosome Development and Manufacturing Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 101 Bio
2. 10x Genomics
3. Aegle Therapeutics
4. Aethlon Medical 
5. AlfatestLab
6. American Association for the Advancement of Science (AAAS)
7. American Society for Bone and Mineral Research (ASBMR)
8. Amgen
9. AMSBIO
10. Anjarium Biosciences
11. Anopoli Biomedical Systems
12. Aruna Bio
13. ASN Events
14. Beth Israel Deaconess Medical Center
15. BioCat
16. BioPharma Asia
17. Biosyyd
18. BioTech Pharma Summit
19. Bio-Techne
20. BioXpedia
21. Broad Institute of MIT and Harvard
22. Cambridge Bioscience
23. Capital Biosciences 
24. Capricor Therapeutics
25. CD Bioparticles
26. Cell Guidance Systems
27. Cellex 
28. Cellular Biomedicine Group (CBMG)
29. Center for Biologics Evaluation and Research (CBER)
30. CHA Biotech
31. Ciloa 
32. Clara Biotech
33. Codiak BioSciences
34. Craif
35. Creative Bioarray
36. Creative Biolabs
37. Creative Biostructure
38. Creative Proteomics
39. Curexsys
40. David H. Murdock Research Institute (DHMRI)
41. Direct Biologics
42. Editas Medicine
43. EriVan Bio
44. European Society of Cardiology (ESC)
45. Esco Aster
46. EV Therapeutics 
47. Evercyte
48. EVerZom
49. Evox Therapeutics
50. Excilone
51. Excipio Technologies
52. EXIT071
53. ExoCoBio
54. Exogenus Therapeutics
55. Exolitus
56. ExoModTech
57. Exopharm
58. Exosome Diagnostics
59. Exosome Sciences (Acquired by Aethlon Medical)
60. Exosome Plus
61. Exosomics
62. ExoVectory
63. Finnish Red Cross
64. Florica Therapeutics
65. Frontage Laboratories
66. Fusion Conferences
67. GeneCopoeia
68. George Mason University
69. Goodwin Biotechnology
70. HansaBioMed Life Sciences (Acquired by Lonza)
71. Hanson Wade
72. Harvard University
73. Henry Ford Health System
74. ILIAS Biologics 
75. Immunostep
76. Innovex Therapeutics
77. Inscripta
78. Intezyne Technologies
79. Italian Association of Cell Culture (AICC)
80. Izasa Scientific
81. Izon Science
82. Jazz Pharmaceuticals
83. Kimera Labs
84. Lifeasible
85. Lonza
86. Luminous BioSciences 
87. Macrogen
88. Mahe Technologies
89. Mantra Bio
90. Marin Biologic Laboratories
91. Massachusetts General Hospital
92. Massachusetts Institute of Technology
93. MDimune
94. Merck
95. Miltenyi Biotec
96. Moderna
97. Nanovex Biotechnologies 
98. NanoView Biosciences
99. National Cancer Institute (NCI)
100. National Institute for Health and Medical Research (INSERM) (Acquired by Inserm Transfert)
101. National Taiwan University Hospital
102. NeuroDex
103. Norgen Biotek
104. Novus Biologicals (Acquired by Bio-Techne)
105. NurExone Biologic
106. Ocean Ridge Biosciences
107. Omnigene Medical technologies
108. OmniSpirant
109. OPTOLANE Technologies
110. Organicell Regenerative Medicine
111. Pathways to Stem Cell Science
112. Progenity
113. QIAGEN
114. Quantum Design
115. Ragon Institute of MGH, MIT and Harvard
116. Regeneron Pharmaceuticals
117. ReNeuron
118. RoosterBio
119. Ruijin Hospital
120. Sanford Burnham Prebys Medical Discovery Institute
121. Sarepta Therapeutics
122. System Biosciences (SBI)
123. SelectBIO
124. SMi Group
125. Spectradyne
126. Stanford University
127. Sumika Chemical Analysis Service
128. System Biosciences
129. Takeda
130. The Cell Factory 
131. University Medical Center Utrecht
132. University of Texas
133. Thermo Fisher Scientific
134. Thomas Jefferson University
135. Toray Industries
136. Tymora Analytical Operations
137. UCL Translational Research Office 
138. uFluidix
139. University Hospital Bonn (UKB)
140. Unicyte
141. University of California
142. University of Paris, France
143. Vanderbilt University
144. Vesigen Therapeutics
145. Vironova
146. VivaZome Therapeutics
147. Xollent Biotech
148. XOStem